Vemlidy tablets 25 mg for hepatitis B (Tenofovir)

General information on Japanese Vemlidy tablets 25 mg for hepatitis B (Tenofovir)

Package details: 30 tablets

Manufacturer: Gilead Sciences Co. Ltd., Japan

Active ingredient: tenofovir alafenamide (chemical formula C25H33N6O9P)

Medical effect: Vemlidy tablets are effective for the treatment of hepatitis B in adults with stable (compensated) liver disease.

Contraindications and precautions: do not use in the following categories of patients:

• patients with end stage renal disease (ESRD),
• patients with HIV-1 infection,
• pregnant women,
• breastfeeding women.

If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Do not stop taking Vemlidy tablets abruptly because it may flare up HBV infection.

Dosage and administration of Japanese Vemlidy tablets 25 mg for hepatitis B (Tenofovir)

Adults should take 1 tablet 1 time a day, always at the same time. The patients on dialysis should take the tablet after the dialysis. The dosage may be adjusted by the consulting doctor due to age and symptoms. The length of the treatment course should be prescribed by the consulting doctor, typically 6-12 months or more.

How effective are Vemlidy tablets 25 mg from Japan for hepatitis B (Tenofovir)?

Each Vemlidy tablet contains 25 mg of tenofovir alafenamide, a nucleoside analog reverse transcriptase inhibitor for hepatitis B virus. It works by works by interfering with an enzyme called DNA polymerase and blocking replication of hepatitis B virus. Vemlidy tablets are effective for lowering the amount of HBV in the body, preventing the infection of the new liver cells, improving the inflammation and scar tissue in the liver. By this, Vemlidy tablets also reduce the risk of developing cirrhosis, liver failure and liver cancer.

Who should use Vemlidy tablets 25 mg from Japan?

Studies show that 94% of patients receiving tenofovir alafenamide had HBV DNA less than 29 IU/mL at the 48 week of treatment (M. Buti, E. Gane et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for the Treatment of Patients With HBeAg-negative Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial // The Lancet Gastroenterology and Hepatology, 2016, November, 1(3): 196-206). Moreover, Vemlidy tablets did not show any drug resistance in the clinical study. And the decreases in bone mineral density are significantly less than in patients taking tenofovir disoproxil fumarate due to better delivery of tenofovir alafenamide to hepatocytes. In other words, Vemlidy tablets have improved renal and bone safety.